Cargando…

170. Antimicrobial Use Before and During COVID-19 – Data from 108 VA Facilities

BACKGROUND: Increased antibiotic prescribing rates during the early phases of the COVID-19 pandemic have been widely reported. We previously reported that while both antibiotic days of therapy (DOT) and total days present (DP) declined in the first 5 months of 2020 at Veterans Affairs (VA) acute car...

Descripción completa

Detalles Bibliográficos
Autores principales: Goetz, Matthew B, Willson, Tina M, Stevens, Vanessa W, Graber, Christopher J, Rubin, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643721/
http://dx.doi.org/10.1093/ofid/ofab466.372
_version_ 1784609916960374784
author Goetz, Matthew B
Goetz, Matthew B
Willson, Tina M
Stevens, Vanessa W
Graber, Christopher J
Rubin, Michael
author_facet Goetz, Matthew B
Goetz, Matthew B
Willson, Tina M
Stevens, Vanessa W
Graber, Christopher J
Rubin, Michael
author_sort Goetz, Matthew B
collection PubMed
description BACKGROUND: Increased antibiotic prescribing rates during the early phases of the COVID-19 pandemic have been widely reported. We previously reported that while both antibiotic days of therapy (DOT) and total days present (DP) declined in the first 5 months of 2020 at Veterans Affairs (VA) acute care facilities nationwide relative to the comparable period in 2019, antibiotic DOT per 1000 DP increased by 11.3%, largely reversing declines in VA antimicrobial utilization from 2015 – 2019. We now evaluate whether these changes in antibiotic use persisted throughout the COVID-19 pandemic. METHODS: Data on antibacterial use, patient days present, and COVID-19 care for acute inpatient care units in 108 VA level 1 and 2 facilities were extracted through the VA Informatics and Computing Infrastructure; level 3 facilities which provide limited acute inpatient services were excluded. DOT per 1000 DP were calculated and stratified by CDC-defined antibiotic classes. RESULTS: From 1/2020 to 2/2021, care for 34,096 COVID-19 patients accounted for 13% of all acute inpatient days of care in the VA. Following the onset of COVID-19 pandemic, monthly total acute care antibiotic use increased from 533 DOT/1000 DP in 1/2020 to a peak of 583 DOT/1000 DP in 4/2020; during that month COVID-19 patients accounted for 13% of all DP (Figure). In subsequent months, total antibiotic use declined such that for the full year the change of antibiotic use from 2019 to 2020 (a decrease of 18 DOT/1000 DP) was similar to the rate of decline from 2015 to 2019 (mean decrease of 13 DOT/1000 DP; Table). The decreased DOT/1000 DP from 5/2020 to 2/2021 occurred even as the percentage of all DP due to COVID-19 peaked at 14 - 24% from 11/2020 to 2/2021. [Image: see text] [Image: see text] CONCLUSION: Although rates of antibiotic use increased within the VA during the early phases of the COVID-19 pandemic, rates subsequently decreased to below previous baseline levels even as the proportion of COVID-19 DP spiked between 11/2020 and 02/2021. Although the degree to which the initial increase in antibiotic use is attributable to concerns of bacterial superinfection versus changes in case-mix (e.g., decreased elective admission) remains to be assessed, these data support the continued effectiveness of antimicrobial stewardship programs in the VA. DISCLOSURES: Matthew B. Goetz, MD, Nothing to disclose
format Online
Article
Text
id pubmed-8643721
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86437212021-12-06 170. Antimicrobial Use Before and During COVID-19 – Data from 108 VA Facilities Goetz, Matthew B Goetz, Matthew B Willson, Tina M Stevens, Vanessa W Graber, Christopher J Rubin, Michael Open Forum Infect Dis Poster Abstracts BACKGROUND: Increased antibiotic prescribing rates during the early phases of the COVID-19 pandemic have been widely reported. We previously reported that while both antibiotic days of therapy (DOT) and total days present (DP) declined in the first 5 months of 2020 at Veterans Affairs (VA) acute care facilities nationwide relative to the comparable period in 2019, antibiotic DOT per 1000 DP increased by 11.3%, largely reversing declines in VA antimicrobial utilization from 2015 – 2019. We now evaluate whether these changes in antibiotic use persisted throughout the COVID-19 pandemic. METHODS: Data on antibacterial use, patient days present, and COVID-19 care for acute inpatient care units in 108 VA level 1 and 2 facilities were extracted through the VA Informatics and Computing Infrastructure; level 3 facilities which provide limited acute inpatient services were excluded. DOT per 1000 DP were calculated and stratified by CDC-defined antibiotic classes. RESULTS: From 1/2020 to 2/2021, care for 34,096 COVID-19 patients accounted for 13% of all acute inpatient days of care in the VA. Following the onset of COVID-19 pandemic, monthly total acute care antibiotic use increased from 533 DOT/1000 DP in 1/2020 to a peak of 583 DOT/1000 DP in 4/2020; during that month COVID-19 patients accounted for 13% of all DP (Figure). In subsequent months, total antibiotic use declined such that for the full year the change of antibiotic use from 2019 to 2020 (a decrease of 18 DOT/1000 DP) was similar to the rate of decline from 2015 to 2019 (mean decrease of 13 DOT/1000 DP; Table). The decreased DOT/1000 DP from 5/2020 to 2/2021 occurred even as the percentage of all DP due to COVID-19 peaked at 14 - 24% from 11/2020 to 2/2021. [Image: see text] [Image: see text] CONCLUSION: Although rates of antibiotic use increased within the VA during the early phases of the COVID-19 pandemic, rates subsequently decreased to below previous baseline levels even as the proportion of COVID-19 DP spiked between 11/2020 and 02/2021. Although the degree to which the initial increase in antibiotic use is attributable to concerns of bacterial superinfection versus changes in case-mix (e.g., decreased elective admission) remains to be assessed, these data support the continued effectiveness of antimicrobial stewardship programs in the VA. DISCLOSURES: Matthew B. Goetz, MD, Nothing to disclose Oxford University Press 2021-12-04 /pmc/articles/PMC8643721/ http://dx.doi.org/10.1093/ofid/ofab466.372 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Goetz, Matthew B
Goetz, Matthew B
Willson, Tina M
Stevens, Vanessa W
Graber, Christopher J
Rubin, Michael
170. Antimicrobial Use Before and During COVID-19 – Data from 108 VA Facilities
title 170. Antimicrobial Use Before and During COVID-19 – Data from 108 VA Facilities
title_full 170. Antimicrobial Use Before and During COVID-19 – Data from 108 VA Facilities
title_fullStr 170. Antimicrobial Use Before and During COVID-19 – Data from 108 VA Facilities
title_full_unstemmed 170. Antimicrobial Use Before and During COVID-19 – Data from 108 VA Facilities
title_short 170. Antimicrobial Use Before and During COVID-19 – Data from 108 VA Facilities
title_sort 170. antimicrobial use before and during covid-19 – data from 108 va facilities
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643721/
http://dx.doi.org/10.1093/ofid/ofab466.372
work_keys_str_mv AT goetzmatthewb 170antimicrobialusebeforeandduringcovid19datafrom108vafacilities
AT goetzmatthewb 170antimicrobialusebeforeandduringcovid19datafrom108vafacilities
AT willsontinam 170antimicrobialusebeforeandduringcovid19datafrom108vafacilities
AT stevensvanessaw 170antimicrobialusebeforeandduringcovid19datafrom108vafacilities
AT graberchristopherj 170antimicrobialusebeforeandduringcovid19datafrom108vafacilities
AT rubinmichael 170antimicrobialusebeforeandduringcovid19datafrom108vafacilities